Williams, Dylan MBandres-Ciga, SaraHeilbron, KarlHinds, DavidNoyce, Alastair J2023-02-092023-02-092020-08-19Williams DM, Bandres-Ciga S, Heilbron K, Hinds D, Noyce AJ; 23andMe Research Team, et al. Evaluating Lipid-Lowering Drug Targets for Parkinson's Disease Prevention with Mendelian Randomization. Ann Neurol. 2020 Nov;88(5):1043-1047.http://hdl.handle.net/10668/16149Long-term exposure to lipid-lowering drugs might affect Parkinson's disease (PD) risk. We conducted Mendelian randomization analyses where genetic variants indexed expected effects of modulating lipid-lowering drug targets on PD. Statin exposure was not predicted to increase PD risk, although results were not precise enough to support benefits for prevention clearly (odds ratio [OR] = 0.83; 95% confidence interval [CI] = 0.65, 1.07). Other target results were null, except for variants indicating Apolipoprotein-A5 or Apolipoprotein-C3 inhibition might confer protection. These findings suggest peripheral lipid variation may not have a prominent role in PD etiology, but some related drug targets could influence PD via alternate pathways. ANN NEUROL 2020;88:1043-1047.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Anticholesteremic AgentsApolipoprotein A-VApolipoproteins BCholesterol, LDLCholesterol, VLDLHumansHypolipidemic AgentsMendelian Randomization AnalysisParkinson DiseasePolymorphism, Single NucleotideTreatment OutcomeTriglyceridesresearch article32841444open accessAnálisis de la aleatorización mendelianaEnfermedad de ParkinsonHipolipemiantesHumanosPolimorfismo de nucleótido simpleResultado del tratamientoTriglicéridosVLDL-Colesterol10.1002/ana.258801531-8249PMC7693098https://doi.org/10.1002/ana.25880https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693098/pdf